XML 26 R16.htm IDEA: XBRL DOCUMENT
v3.23.1

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2023
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES |
Schedule of revenues disaggregated by business operations and timing of revenue recognition | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Month Period Ended:
​ | ​ | March 31, | ​ | March 31,
​ |  | 2023 |  | 2022
Research and development services (over-time) | ​ | $ | 87,907 | ​ | $ | 219,898
Clinical laboratory testing services (point-in-time) | ​ | ​ | 3,003,022 | ​ | ​ | 4,331,867
Clinical laboratory testing services (over-time) | ​ | ​ | 938,080 | ​ | ​ | 1,158,375
Product and authentication services (point-in-time): | ​ |  | ​ | ​ |  | ​
Supply chain | ​ |  | 27,636 | ​ |  | 115,463
Large Scale DNA Production | ​ | ​ | 253,626 | ​ | ​ | —
Asset marking | ​ |  | 97,343 | ​ |  | 141,657
MDx test kits and supplies | ​ | ​ | — | ​ | ​ | 180,023
Total | ​ | $ | 4,407,614 | ​ | $ | 6,147,283
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six Month Period Ended:
​ | ​ | March 31, | ​ | March 31,
​ |  | 2023 |  | 2022
Research and development services (over-time) | ​ | $ | 213,964 | ​ | $ | 325,591
Clinical laboratory testing services (point-in-time) | ​ | ​ | 6,077,436 | ​ | ​ | 6,205,589
Clinical laboratory testing services (over-time) | ​ | ​ | 2,377,961 | ​ | ​ | 2,484,775
Product and authentication services (point-in-time): | ​ | ​ | ​ | ​ | ​ | ​
Supply chain | ​ |  | 439,973 | ​ |  | 527,295
Large Scale DNA Production | ​ |  | 381,131 | ​ |  | —
Asset marking | ​ | ​ | 179,901 | ​ | ​ | 246,895
MDx test kits and supplies | ​ |  | — | ​ |  | 522,844
Total | ​ | $ | 9,670,366 | ​ | $ | 10,312,989
​
Schedule of opening and closing contract balances | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | October 1, | ​ | March 31, | ​ | $
​ |  | Balance sheet classification |  | 2022 |  | 2023 |  | change
Contract liabilities |  | Deferred revenue | ​ | $ | 563,557 | ​ | $ | 283,298 | ​ | $ | 280,259
​
Schedule of reconciliation of cash, cash equivalents and restricted cash to amounts shown in statement of cash flows | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | September 30,
​ |  | 2023 |  | 2022
Cash and cash equivalents | ​ | $ | 12,287,228 | ​ | $ | 15,215,285
Restricted cash | ​ |  | 750,000 | ​ |  | —
Total cash, cash equivalents and restricted cash | ​ | $ | 13,037,228 | ​ | $ | 15,215,285
​
Schedule of anti-dilutive securities not included computation of net loss per share | ​
​ | ​ | ​ | ​ | ​
​ |  | 2023 |  | 2022
Warrants | ​ | 7,295,588 | ​ | 2,239,963
Restricted Stock Units | ​ | 282,640 | ​ | —
Stock options | ​ | 2,206,336 | ​ | 1,067,614
Total | ​ | 9,784,564 | ​ | 3,307,577
​

X
- Definition Tabular disclosure of the components of cash, cash equivalents and restricted cash and cash equivalents. + References No definition available. + Details
Name: | apdn_ScheduleOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock
Namespace Prefix: | apdn_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration